Cellular phenotypes are a 'read-out' of the complex interplay of genetic and epigenetic determinants that ultimately define a unique proteome and thereby specify cellular identity. However, modulation of the proteome itself is emerging as a key concept in our understanding of the molecular basis of phenotypic traits. Many studies over the past two decades have highlighted how regulated changes in protein modifications, such as phosphorylation and glycosylation, contribute to cellular phenotypes by altering protein abundance, function and localization. Such changes can in turn have an impact on complex regulatory pathways that control cellular phenotypes. But posttranslational modifications are not the whole story; changes in protein conformation might also explain many phenotypic switches, albeit by a mechanism that is not yet fully understood.
The prototypical and perhaps most extensively characterized examples of protein conformation-based inherited phenotypic traits are those defined by the protein aceous infectious particles known as prions. These factors were originally identified as infectious entities and are associated with a group of communicable neurodegenerative diseases in mammals 1, 2 ; these diseases are known as transmissible spongiform encephalo pathies (TSEs) and include Creutzfeldt-Jakob disease (CJD) and kuru in humans, scrapie in sheep and bovine spongiform encephalopathy (BSE) in cattl e. The causative agent of TSEs is resistant to treatments that damage nucleic acids 1, 3 . The fact that prions could function as infectious agents despite the absence of a nucleic acid genome led to the formulation of the 'protein-only' or prion hypothesis 1, 3 . According to this theory, the TSE agent is a self-perpetuating conformer of a host protein known as prion protein (PrP) 1 . There are two conformer s of this protein: cellular PrP (PrP C ), which is the normal conformer, and scrapie PrP (PrP Sc ), which is the infectious conformer. PrP Sc was predicted to 'replicate' during infection by contacting specific regions on PrP C to recruit this protein and convert it into PrP Sc . A wealth of genetic and biochemical data now support this concept of conformational replication, leading to its near-universal acceptance.
Prions have also been found in two species of fungi, the yeast Saccharomyces cerevisiae and the multi cellular fungus Podospora anserina 4 
. These functionall y unrelated fungal proteins can, like PrP, individually adopt a range of physical forms and transition between these states under physiological conditions. In both mammals and fungi, these physical transitions specify new phenotypes that may result from alter ations to the normal function of the protein (gain-of-function and/or loss-of-function), the cellular response to the new protein conformation and/or the rate of accumulation of the altered form. Remarkably, these alternative conformers, each with a distinct but stable three-dimensiona l shape, are self-replicating and can be transferred between cells or organisms, allowing the associated traits to be transmitted as infectious diseases (as occurs in mammals 5 ) or inherited through cell division (as occurs in fungi
Prion
A structurally altered form of a protein that can impose that form on a previously correctly folded form of the same protein and hence propagate the prion form by inheritance (yeast prions) or in an infectious manner (mammalian prion protein (PrP)).
Conformer
One of many different stable tertiary structures that can be taken up by a single polypeptide chain.
our understanding of the mechanistic basis of prion propagation and transmission is in its infancy, but it is clear that these processes exist and that they ensure a level of genetic stability for prion-based epigenetic determinants that is in line with that of nucleic acid-based genetic determinants.
In this Review we examine the expanding range of cellular processes and complex phenotypes that are determined by these epigenetic elements in fungi and in mammals, and discuss how the process of conformational self-replication provides a framework for understanding the molecular basis of prion-associated phenotypes. As the number of identified prion proteins increases, we suggest that the prion mechanism should no longer be considered as a disease-causing biological anomaly but should be thought of as a novel regulator of cell phenotype.
Prion-associated phenotypes in fungi Fungal prions have been identified through classical genetic studies, sequence-based algorithms and genetic screens [6] [7] [8] [9] 
. To date, nine proteins have been confirmed as fungal prions (TABLE 1) , and at least another 20 proteins may potentially fall into this class. Remarkably, fungal prions affect the activity and/or regulation of several cellular processes, with many having important roles in global gene regulation at either the transcriptional or post-transcriptional levels (TABLE 1) . Because of their roles in regulating the expression of genetic information, prion proteins could indirectly affect a wide range of co-regulate d cellular processes.
[ 12, 13 , suggesting that the conversion of Sup35 to its prion form compromises its activity in translation termination by sequestration. This reduction in release activity allows near-cognate tRnAs to mistranslate a stop codon as a sense codon. Sup35 proteins from many closely related Saccharomyces species retain the ability to behave as prions when expressed in the S. cerevisiae cytoplasm 14 , indicating that [PSI + ] could be a newly appreciated but conserved epigenetic mechanism for regulating translation termination and reading-frame maintenance. This change in translational fidelity affects a broad range of cellular phenotypes either directly or indirectly.
The [PSI + ]-dependent suppression of specific nonsense mutations generates changes in phenotype that can be readily assayed. However, there are several complex phenotypes that are [PSI + ] dependent but are not simply attributable to suppression of a specific nonsense mutation; these phenotypes include altered sensitivity to a range of physical stresses such as heat 15 and toxic chemical agents 16, 17 . Such prion-mediated effects probably reflect a more global perturbation of the proteome that could arise through specific effects on a regu latory factor or alternatively through the extension of an open reading frame (oRF) by stop codon read-through, which could modify the function of the encoded protein or inactivate it. Despite the existence of opposing forces that ensure translational fidelity, such as the context of the stop codon 18 and the non-stop mRnA decay pathway 19 , recent studies have uncovered support for each of these mechanisms that have the potential to mediate global perturbations of the proteome. For example, ornithine decarboxylase antizyme 1, which is encoded by OAZ1, is a negative regulator of polyamine biosynthesis that is translated from two overlapping out-of-frame oRFs by a +1 frameshift 20 (FIG. 1a) (TABLE 1) . Prion-based epigenetic systems may have evolved because they can rapidly modify a cellular phenotype in response to a changing environment without introducing a change in the sequence and function of the genome.
Box 2 | Can you identify a prion protein from its amino acid sequence?
Although prions that affect the host phenotype or cause disease have been identified and verified only in fungi and mammals, it is unlikely that they are restricted to these two groups of organisms. One important question that we are now close to answering is whether we can identify a prion protein from its sequence. Soon after their discovery in fungi, it emerged that there are some sequence features that are shared by the various yeast prion proteins, in particular the presence of a region of the protein (known as the prion-forming domain (PrD)) that contains an atypically high density of Gln and Asn residues and that is conformationally flexible 8, 9 . A high density of Gln residues in a protein makes it prone to aggregate, but it is the high density of Asn residues that is crucial for prion propagation 9 . Remarkably, it is the amino acid composition, rather that its sequence, that is essential for determining prion potential . In addition to Gln-Asn content, some prion-forming proteins, such as Sup35 and to a lesser extent rich in Asn and Gln protein 1 (Rnq1), have short oligopeptide repeats with sequence similarity to a series of octapeptide repeats found in prion protein (PrP), suggesting that such sequences may be important for prion propagation 142 . One approach has identified 200 proteins with this architecture in Saccharomyces cerevisiae, although many of these do not satisfy the genetic and/or biochemical criteria to be designated as prions 9 . The fact that the PrD of the Podospora anserina HET-S prion protein lacks both Asn and Gln residues but can be efficiently propagated as the [Het-s] prion in either P. anserina 32 or S. cerevisiae
tRNA-mediated nonsense suppression
The translation of a termination codon by a tRNA with a mutation in its anticodon. This can result in partial restoration of function to the encoded protein when the codon is located within the open reading frame (a nonsense mutation).
+1/-1 ribosomal frameshifting
A net shift in the translation of an open reading frame by one base, either in the 3′ direction (+1) or 5′ direction (-1), that is directed by a specific signal in the mRNA sequence.
Vegetative incompatibility
Death of a multinucleate heterokaryon arising from the fusion of two different strains of a fungus, thereby preventing the transfer of cytoplasmic components from one strain to another.
Heterokaryon
Co-existence of two or more genetically different nuclei in a common cytoplasm.
Also, the phosphodiesterase 2 (PDE2) oRF, which encodes a high-affinity cyclic AMP phospho diesterase, is extended in [PSI + ] cells, leading to a destabilization of the encoded enzyme and an increase in cAMP levels 22 (FIG. 1b) 24 ) regulate the transcription of ~400 different genes, many of which contribute to a range of key cell ular pathways. The newly described Mot3 (REF. 9 ) also has a broad range of target genes, including those that are important for cell wall remodelling under anaerobic conditions and for ergosterol biosynthesis, and it potentially affects vacuole function 25 . Sfp1 coordinates the expression of ribosomal proteins and factors that control ribosome biogenesis 26 . The transcriptional effects of these factors are mediated by their association with larger protein complexes (for example, the SwI-SnF chromatinremodelling complex, the Cyc8-Tup1 and Mot3-regulation by oxygen gene 1 (Rox1) co-repressor complexes, and Sfp1 regulation by target of rapamycin complex 1 (ToRC1)).
The switch to the prion form may affect these associations and thereby alter the expression of a large portion of the yeast transcriptome. This idea has been experimentally confirmed for strains carrying the [OCT + ] prion, in which the Cyc8-Tup1 co-repressor complex becomes inactive and genes such as CYC7 (which encodes cytochrome c2) and SUC2 (which encodes invertase) become derepressed 24 (FIG. 2B) .
[URE3], the first fungal prion to be discovered, also exemplifies the phenotypic consequences of a transcriptional regulator -in this case ure2 -switching to a prion form. In its soluble non-prion form, ure2 binds two transcriptional activators (Gln3 and Gat1) in the cytoplasm, preventing their transit into the nucleus 27, 28 . This sequestration represses the transcription of target genes and prevents the use of poor nitrogen sources when preferred sources, such as ammonia, are available (FIG. 2Aa) . In [URE3] cells, ure2 aggregates in the cytosol and cannot retain Gln3 and Gat1, resulting in the activation of the transcriptional programme that is needed to use alternative nitrogen sources, thereby phenocopying loss-of-function ure2 mutations (FIG. 2Ab) . ure2 has also been implicated in cellular responses to heavy metals and oxidative stress that are independent of its transcriptional regulatory role 29 , so the switch to the [URE3] form could affect additional cellular phenotypes. . when a strain of the fungus carrying the [Het-s] prion meets a strain that expresses an allele of het-s (het-S) that encodes a non-prion-forming form of the protein (known as HET-S), the mixed heterokaryon formed on cell fusion dies 32 (FIG. 2C) . This cell death blocks horizontal transmission of the prion and may represent a form of innate immunity 33 . Although the mechanism of cell death remains unclear, this event is only triggered if the [Het-s] prion is present in one of the two strains; a cross between a het-s strain expressing the non-prion soluble form of the protein ([Het-s*]) or a Δhet-s strain is compatible 31, 32 . Intriguingly, this incompatibility depends on the ability of HET-S to adopt a prion conformation in the presence of the [Het-s] prion, suggesting that either these mixed complexes themselves are the toxic form or they indirectly induce toxicity on co-aggregation 34 .
Prion-based gain-of-function phenotypes. The [PSI
An apparent gain-of-function prion phenotype is also linked to rich in Asn and Gln protein 1 (Rnq1) of S. ] inducibility' and is the only prion reported to exist in non-laboratory strains of S. cerevisiae to date 38, 39 . why the prion form of Rnq1 but not its soluble form 29, 43 , but the failure to detect these prions in natural isolates may not be sufficient to discount a potentially beneficial role for these phenotypic states. In the case of [PSI + ], Sup35 homologues in Saccharomyces species have retained the ability to adopt a prion conformation in a laboratory setting 14 , and under these conditions the [PSI + ] state is bene ficial in the short term (that is, in response to chemica l or physical threats) 15, 17, 21 , and perhaps in the long term through adaptation and ultimately the evolution of new genetic traits 16, 17, 44, 45 . A more broad and syste matic survey of prion determinants in natural isolates and in diverse niches will undoubtedly shed light on the costs and benefits of these protein conformational and phenotypic switches for fungi.
Prion-associated phenotypes in mammals
Fungal prion proteins adopt self-replicating conformers that are largely benign to the host under standard laboratory conditions, whereas the appearance of similar conformers in mammals is most typically associated with the emergence of disease. Despite this clearly disadvantageous phenotype, mounting evidence suggests that prion conversions in mammals, similarly to their fungal counterparts, are a mechanism for regulating protein function.
Gain-of-function amyloids.
A good model to study the effects of conformational change on normal protein activity is a group of endogenous mammalian proteins that have the ability to form amyloids. In vitro, these proteins form similar structures to prions, but their biological effects (transmissible versus non-transmissible) are different.
Amyloidogenic proteins can undergo a prion-like self-replicating change in conformation, leading to the build-up of amyloid deposits in vivo. These amyloidoses can be distinguished from the prion diseases by their lack of infectivity. However, recent studies have revealed that, within individual organisms, some of these proteins show a similar behaviour to prions, whereby the amyloid form can be propagated from one cell to a neighbouring cell by exogenous transfer of these aggregates 46 . Among these proteins are the amyloids associated with Alzheimer's disease (amyloid-β) 47 , Huntington's disease (polyglutamine) 48 and Parkinson's disease (α-synuclein) 49 . Because these prion-like amyloids lack a complete infectious cycle, they have been termed prionoids 50 . How do these diseases relate to the normal function of the protein? The emerging consensus is that the toxicity associated with the amyloidoses represents a newly acquired activity that is linked to the alter native conformation 51 . This hypothesis is consistent with our current understanding of the gain-of-function phenotypes of some fungal prions and the identification of proteins in bacteria and the invertebrate Aplysia spp. for which the normal biological activity is associated with the amyloid form 52, 53 . Prion Rnq1 Prion Sup35 Non-prion Sup35
Non-prion Ure2
Melanosome An organelle within melanocytes in which melanin is generated and stored.
Recently, this concept of functional amyloid forms has been extended to vertebrates. For example, amyloid formation by a proteolytic fragment of the transmembrane glycoprotein premelanosomal protein 17 (PME17) is required for the maturation of melanosomes and stimulates the synthesis of melanin 54, 55 . Furthermore, peptide and protein hormone precursors (known as prohormone s) are stored in an amyloid form in pituitary secretory granules, and this can be reversed by dilution of the amyloid fibrils in vitro, which suggests that amyloids are an active storage form 56 . Therefore, the amyloid form can, in principle, act as a mechanism to regulate protein function in mammals.
PrP as a disease-causing agent in vertebrates. In the case of the TSEs, a clear and irrefutable role for PrP in the appearance, phenotypic manifestation and spread of disease has been established, primarily through studies in transgenic mice. PrP is the major constituent of biochemically enriched preparations of the TSE agent 2 , and mice devoid of PrP cannot replicate the infectious agent and are resistant to TSEs following challenge 57 . In addition, strong evidence supports a direct role for PrP in clinical disease. Depletion of PrP after infection extends incubation times and reverses both neuropathology and behavioural defects induced by the infection 58, 59 . These observations are consistent with a functional role for PrP in TSE aetiology. However, important questions remain: what is the molecular basis of TSE-associated neurotoxicit y and how does it relate to the normal function of PrP?
In fungi, the classification of prion-associated phenotypes as gain of function or loss of function is defined in relation to the null phenotype; however, a similar comparison for PrP and the TSEs has proved more complex. Early attempts to identify a function for PrP were hampered by the absence of overt phenotypic defects in PrP-null mice and of conserved structural or sequence motifs 57 . Despite these initial setbacks, subsequent studies have shown that PrP-null mice differ from their wild-type counterparts in many activities, including circadian cycles, neuroprotection, synaptic function, lymphocyte activation, cell adhesion, stem cell renewal and pro liferation, and olfaction 57, [60] [61] [62] . Furthermore two recent studies have uncovered new roles for PrP. During zebrafish development, knockdown of either of the duplicated PrP genes induces loss of cell adhesion and altered localization of epithelial-cadherin and FYn Tyr kinase, phenotypes that are suppressed by the expression of mouse PrP 63 . In addition, in adult mice regulated proteolysis and expression of PrP on the neuronal cell surface are required for the maintenance of myelination through a non-cell autonomous route 64 . Together, these studies indicate that PrP might have a pleiotropic role in vivo, perhaps mediating its broad effects by affecting cell signalling pathways 65 . So, is TSE pathogenesis linked to a loss-of-function or a gain-of-function phenotype for PrP? our current knowledge suggests that the answer to this question lies somewhere in between the two possibilities. Although the absence of neurodegeneration in PrP-null mice was originally considered to be incompatible with a loss-offunction model for prion diseases, subsequent studies have shown that the expression of some PrP fragments induces spontaneous neurodegeneration in PrP-null mice 57, 66, 67 . Based on these observations, PrP toxicity during TSE infection could be explained as a loss of some PrP functions but not of others 65 . Consistent with this idea, PrP must be expressed on the surface of neurons to mediate TSE pathogenesis following infection [68] [69] [70] , suggesting that normal localization of the protein is required to elicit neurotoxicity. However, a gain-of-function model 
Strain 'mutation' or adaptation
The conversion of one prion conformer to another, either spontaneously or in response to a new environment.
for the TSEs, as has been suggested for the amyloidoses (see above), cannot be ruled out at this point. In this model, conformational conversion of PrP to the prion state would be predicted to be neurotoxic to the host. The putative neurotoxic species was originally proposed to be PrP Sc , which accumulates during the terminal stages of disease and in purified preparation of the infectious agent 2 ; however, the presence of PrP Sc correlates poorly with clinical disease 71, 72 . Indeed, mice that are heterozygous for a PrP disruption progress to the terminal stage of disease more slowly than their wild-type counterparts despite the accumulation of similar levels of PrP 
Prion self-replication and phenotypes
Although the mechanism by which misfolding of PrP alters the function of the protein to mediate TSE pathogenesis remains unknown, mounting evidence suggests that the process of conformational self-replication itself provides a robust framework for understanding the molecular basis of prion phenotypes both in mammals and fungi. The striking mechanistic parallels between these two systems further support the idea that prions can function as basic regulatory molecules in metazoans.
Conformational self-replication. The prion hypothesis originally predicted that PrP
Sc catalysed the conversion of the PrP C in the context of a heterodimer of the two forms 1, 3 . However, subsequent studies have revealed that soluble PrP C binds to an oligomer of PrP Sc , which stimulates remodelling following incorporation into these complexes 5 . Such a mechanism will progressively increase the size of prion complexes; however, without evoking a mechanism for generating new templates, this seeded polymerization process cannot account for the exponential increase in infectious titre that is observed over the course of disease in mammals or for the mitotic stability of prion propagation in yeast. what has emerged from mathematical models of prion propagation in both mammals and yeast is that, in addition to the seededpolymerization step, there must be ongoing polymer fragmentation to generate new templates 74 (known as propagons) (FIG. 3) . This prediction is now well supported by experimental studies with yeast prions, in which the fragmentation of prion polymers is catalysed by the molecular chaperone heat shock protein 104 (Hsp104) in conjunction with co-chaperones such as Hsp40 and Hsp70 (REF. 75 ). In mammalian cells, no orthologue of Hsp104 has been described, and it remains to be establishe d how prion complexes are fragmented 76 . unlike a simple heterodimeric conversion mechanism, a multi-step pathway of conformational self-replicatio n allows the formation of intermediate states that could alter prion protein function and thereby explain some aspects of prion biology. For example, although the accumulation of PrP Sc is inconsistent with a direct role for this conformer in TSE pathogenesis, TSE incubation times correlate with PrP expression levels 73, 77, 78 . How might PrP expression induce disease independently of PrP Sc formation? one possibility is that a transient intermediate in the pathway to PrP Sc formation mediates toxicity, a concept that may also explain pathogenesis in other non-transmissible neurodegenerative diseases, such as Alzheimer's disease 5, 51, 79 , and the stability of prion pheno types in fungi 80 . This theory proposes that the rate of replication of the infectious PrP agent strongly influences the rate of formation of the transient toxic species. Efficient replication, such as that observed in the presenc e of increased PrP expression, allows the accumulation of the intermediate form to levels that are sufficient to cause clinical disease.
According to this dynamic model of prion phenotypes, any condition that alters the efficiency of conformational self-replication could affect prion-associated phenotypes by modulating the proportion of the protein that is found in the state that determines the phenotype. Such fine-tunin g, in turn, allows an expansion of the range of pheno types that may be conferred by a single protein without an underlying change in the genetic make-up of the host. Intriguingly, this framework provides a molecular explanatio n for many enigmatic aspects of prion biology.
Prion strains and the evolution of their phenotypes. Prion proteins in both mammals and yeast can adopt a range of self-replicating conformers known as prion strains, which are speculated to confer distinct phenotypes by assembling into aggregates with different physical properties 5, 81, 82 . These differences are thought to specify unique rates of conversion of the soluble protein to the prion state and of fragmentation of prion complexes to generate new propagons. They are therefore thought to determine the efficiency of conformational self-replication, thus providin g a molecular basis for the phenotypes 82 .
In mammals, multiple prion strains may arise in one individual 83, 84 through co-infection 85, 86 or strain 'mutatio n' or adaptation. In the case of mutation or adaptation, prion-associated phenotypes evolve in response to new conditions -such as the presence of compounds that interfere with prion propagation in vivo or the transfer to a new host 10, [87] [88] [89] [90] [91] . The existence of mixtures of prion strains in vivo raises the possibility that prion phenotypes may not simply reflect the physical properties of a single conformer but may instead reflect the collective and dynamic behaviour of the various forms that are present. Indeed, prion strains give rise to markedly different disease characteristics alone than when present in a mixture, including changes in incubation periods 83, 92 , the efficacy of inoculation routes 93 and transmission rates to other species 83, 84, 92 . Similarly, prion disease pathology, duration and clinical symptoms in humans are altered by the co-existence of prion strains 94, 95 . Thus, the interplay between prion strains directly affects prion phenotypes.
How do prion strains interact to produce observable phenotypes? As prion strains can stably persist only if their rates of replication counteract processes that lead to their decline, such as degradation in mammals or di lution through cell division in yeast 74, 82 , the relative efficiencies of conformational self-replication for the interacting strains seem to be crucial in establishing the phenotype of prion mixtures. In mammals, co-inoculation with multi ple prion strains that replicate at different rates almost invariably results in the selection of the faster-replicating strain 96, 97 , but when two different prion strains are introduced at different times (known as superinfection), the outcome is influenced by the interval between inoculations, the inoculum dosage and the routes of inoculation (see below) 98, 99 . Conditions that allow a slower-replicating prion strain to establish an infection before the introduction of a faster-replicating prion strain through the same route either delay or completely block superinfection. These experiments suggest that prion strains compete for a limiting host component that is necessary for establishing a prion infection 100, 101 , and that the competition between existing strains may be similarly affected by the efficiency with which each conformer is replicated in a given tissue 93 . Considering the process of conformational self-replication (FIG. 3) , this component is likely to be the non-prion state protein 101 , a suggestion that is supported by studies in yeast showing that the prion strains that most efficiently incorporate non-prion-state proteins are phenotypically dominant 82, 86, 102 (FIG. 4a) .
Prion resistance and attenuation. The physical interaction between prion proteins is an essential event in conformational self-replication. Thus, it is perhaps not surprising that variations in the amino acid sequence of prion proteins affect their phenotypes in both mammals and yeast. naturally occurring PrP polymorphisms in animals and humans alter the characteristics of the TSE and, in extreme cases, the individual's susceptibility to prion disease 103 . Emerging evidence suggests that sequence variants exert their effects by altering the efficiency of conformational self-replication but that they do so by targeting different steps in the process (FIG. 4b) .
The most well-characterized sequence variant of human PrP is a polymorphism at position 129 with either Met or val (Met/val129) 104, 105 . Although both PrP129 homozygotes (Met/Met or val/val) and heterozygotes are susceptible to prion disease, the genotype at this position affects the pattern of PrP Sc accumulation in the brain and the clinical symptoms, the incubation period and the duration of disease 103 . Disease progression is always more rapid in homozygotes than in hetero zygotes, providing a potential molecular explanation for the overrepresentation of homozygotes in some TSEs 103 . The Met/val129 polymorphism has no effect on the structure Variants interfering with conversion exert their effects at sub-stochiometic levels, as they function at the site of conversion. By contrast, variants interfering with prion aggregate dynamics exert their effects at stochiometric levels because they must incorporate throughout the complex. c | Incompatibility between donor and recipient prion proteins creates a barrier to interspecies transmission. This barrier may reflect an inability of the proteins to associate (not shown) or to adopt compatible conformations. For strains capable of crossing a species barrier, the recipient prion protein may adopt an identical conformation (conformational selection), leading to the conservation of strain identity on transfer. Alternatively, the recipient prion protein may adopt a partially compatible conformation that leads to a change in strain (strain adaptation). or stability of native PrP [106] [107] [108] , but it does affect conformational self-replication in vitro. under certain conditions, mixing Met129 and val129 PrPs (as would occur in heterozygotes) slows down the rate of amyloid growth 109, 110 and favours the formation of an oligomeric intermediate that cannot be directly converted to the amyloid state 109, 111, 112 . Together, these observations suggest that mixtures of Met129 and val129 variants may alter disease progression by limiting the rate of conversion of PrP to the prion form.
Heterozygous interference seems to be a general phenomenon, as both animals and humans that are heterozygous for other PrP alleles show a similar overdominance [113] [114] [115] [116] [117] [118] . Perhaps the most intriguing of these polymorphisms are Glu/lys219 in humans and Gln/Arg171 in sheep. The basic residues (lys or Arg) of these polymorphisms confer resistance to TSEs 103, 117, 119, 120 . The protective effects of these variants correlate with their ability to dominantly inhibit conformational self-replication by the other PrP alleles 121, 122 . notably, this dominant inhibition occurs independently of other factors, suggesting that the wild-type and mutant proteins are incompatible 123, 124 . Although the mechanisms by which PrP sequence variants inhibit conformational self-replication are currently unclear, the different PrP alleles can be distinguished on the basis of the ratio, relative to wild-type protein, at which they become effective inhibitors 122, 123 . According to a mathe matical model 125 , these differences in effective inhibitory concentrations may reflect a targeting of distinct events in conformational self-replication. For example, inhibitors that theoretically function by binding to the ends of linear prion complexes and blocking PrP conversion are predicted to be more effective at lower concentrations than inhibitors that would interfere with other aspects of conformational self-replication, such as fragmentation, which would require binding along the length of the aggregate 125 (FIG. 4b) .
Discovering how changes in replication rates translate into altered phenotypic states requires an assessment of their effects in living organisms, and the yeast prion models provide avenues to further explore these questions. Dominant inhibitory mutations have been isolated in fungal prions and, as is the case for PrP polymorphisms, these mutations interfere with conformational self-replicatio n to varying extents, creating a range of protein-based traits 126, 127 . ]-no-more (PNM) mutations, induce prion loss. other substitutions, known as anti suppressor (ASU) mutations, modestly decrease the efficiency of conformational self-replication, preserving the prion form but allowing the accumulation of soluble and functional Sup35, which reverses the prion phenotype 126 . The most extensively studied PNM mutation is PNM2, which encodes a Sup35 Gly58Asp mutation 127, 128 . This mutant Sup35 incorporates into wild-type [PSI + ] complexes and can support prion propagation on its own 86, [129] [130] [131] . However, PNM2 induces prion loss over many generations 128, 131 , suggesting that this variant interferes with the replication of prion complexes and/or their transmission to daughter cells, ideas that can be directly tested through an assessment of prion protein dynamics in vivo.
Species barrier. In animal models of prion infectivity, a barrier to interspecies transmission has long been appreciated 132, 133 , but renewed interest in this phenomenon has arisen with the realization that variant CJD appeared in the human population following the transfer of BSE from cattle 134, 135 . Mechanistic studies now suggest that species barriers are the outcomes of interactions between prion strains and sequence variants of PrP, which reflect the rate of conformational self-replication in the recipient and provide further support for the link between this process and the stable transmission of prion-associated phenotypes 79 . Species barriers may manifest as a complete block of disease development 83, 136 or, alternatively, as a prolonged incubation period following first passage that is shortened on subsequent passage within the same species 85, 132, 133 . In both cases, replication of the infectious PrP species does occur during the asymptomatic phase 137, 138 , but the toxic species does not reach the threshold concentration required for clinical disease within the organism's natural lifespan 139 . This alteration to the efficiency of conformational self-replication has been linked to differences in the PrP sequences of the donor and recipient. For example, the species barriers between hamster or mink and mice are abolished by heterologous expression of the donor (hamster or mink) PrP in mice 83, 140 ; strikingly, loss of the species barrier has been linked to sequence identity at PrP residues 170 and 174 (REF. 141) . what is the molecular basis of this requirement for sequence compatibility? Prion protein sequence is likely to contribute to the formation of species barriers in many ways: first, it determines the efficiency of interaction between the donor and recipient proteins; second, it defines the range of conformations that a prion protein may adopt 5, 142 ; and third, it determines the stability with which a given conformer is replicated 91 . Indeed, the identity of residues at PrP positions 170 and 174 defines the structure of a loop that can form an intermolecular interface that is common to amyloidogenic proteins 143 , and variations at position 226 correlate with the stability of PrP strains 91 . Thus, a PrP strain can be transmitted between species if it can interact with the recipient protein and if the recipient protein can efficiently replicate the conformation that is imposed.
Perhaps the strongest evidence to support the idea that the efficiency of conformational replication creates the barrier to interspecies prion transmission is the observation of asymmetry in prion conversions. For example, mouse PrP can seed the formation of amyloids by Syrian hamster PrP in vitro, but the opposite does not occur 144 . A comparable asymmetry has been observed between Sup35 homologues from the yeasts Kluyveromyces lactis, Saccharomyces paradoxus, Saccharomyces bayanus and S. cerevisiae 14, 145, 146 , as well as between ure2 homolgues from S. bayanus and S. cerevisiae 147 , and between fragments of Rnq1 (REF. 148 ). Although these reciprocal cross-seedin g reactions involve the same two proteins, they differ in which protein is present in the prion form and, therefore, in which protein serves as the template for conformational conversion. Consistent with this model, there is a close correlation between the ability to template prion formation and the structure adopted: PrP sequence variants that can seed one another spontaneously form amyloid fibrils of similar secondary and quaternary structure in vitro 149 , and PrP and Sup35 molecules adopt differen t structures depending on the template provided 149, 150 . The concept of a conformational replication barrier to interspecies transmission also explains an early observation that such transitions are often accompanied by a change in prion strain 151, 152 . The emergence of a new strain could reflect the selection of a compatible strain from a mixture present in the initial inoculum 85 (FIG. 4c) or, alternatively, a conversion from one conformer to another. Indeed, biological clones of prion strains undergo adaptation and selection following transfer to a new species in vivo and in vitro 97, 153 (FIG. 4c) . Studies in vitro suggest that these transitions may proceed through mixed complexes with heterogenous structures, reflecting only a partial compatibility between the accessible conformations of the two proteins 154 . Such mixed complexes could alter the physical properties of prion aggregates and thereby the efficiency of replication in a manner that is analogous to that described above for dominant inhibitory mutants. Indeed, interspecies transmissions that lead to the emergence of new strains tend to require more passages to stabilize the length of the incubation period in the new host than those that retain their strain identities 97, 152, 153 .
Conclusions
The prion hypothesis first emerged as a radical proposal to explain the transmission of a brain disease in animals. The possibility that PrP, by simply undergoing a change in its tertiary conformation, could switch from a benign form to a self-replicating pathogenic form that induced a long-term and progressive neurodegeneration was no thing short of heretical. Almost 40 years on, the hypothesis has become accepted dogma, but a wealth of recent studies now suggest that the prion concept is entering a new realm of even greater relevance, in which this process is no longer considered simply as an explanation for an unusual and invariably fatal disease. The realization that there are numerous prions in fungi that can radically change the phenotype of the infected host necessitates a rethinking of the role of prions.
we suggest that prions have evolved as epigenetic regulators of phenotype and not as disease-causing agents. Thus, by paralleling the underlying process of conformational self-replication, the prion mechanism provides a robust but dynamic system to modulate protein function and thereby cellular phenotypes. The plasticity of this pathway, its epigenetic nature and its potential to create a continuum of related phenotypes highlight its utility as a common regulatory process that we are only now beginning to appreciate. To date, our knowledge of the effect of prions on species other than fungi has been restricted to the role of PrP Sc in mammalian brain degeneration and death. However, the possibility that synaptic activity in sensory neurons in the brain may be regulated by a prion-like mechanism 53, 155 provides the first clue that prion-mediated control of complex cellular processes might also exist in higher eukaryotes.
